Dr Kathryn Aston-Mourney



Senior Lecturer in Human Biology


Faculty of Health


School of Medicine


Geelong Waurn Ponds Campus


Doctor of Philosophy, University of Melbourne, 2007


Units taught

Post-graduate Medicine

HME101: Medicine 1A Unit Coordinator

Human Biology Topic Coordinator


Under-graduate Medical Biotechnology

HMM103: Cell Technology Unit Chair


2012 JDRF/Maquarie Group Foundation Early-Stage Researcher Travel Grant
2012 CASS Foundation Early Career Researcher Award
2009 Travel Scholarship, Recent Advances in Beta Cell Biology, International Diabetes Federation and University of Toronto
2006 Travel Scholarship, Australian Diabetes Society
2005 Pincus-Taft Young Investigator Award (Awarded by the Australian Diabetes Society)
2005 Travel Scholarship, Australian Diabetes Society
2005  Sanofi aventis Diabetes Partnership Young Investigator Award:   Travel Grant for American Diabetes Association Annual Scientific Meeting 2005
2004 Travel Scholarship, Australian Diabetes Society
2003-2007 Australian Postgraduate Award (Scholarship)
2003 Travel Scholarship, Australian Diabetes Society


Dr. Aston-Mourney has several projects underway focusing on the insulin-secreting beta cells of the pancreas and their dysfunction in diabetes.


Currently accepting expressions of interest from prospective PhD and Honours students.


Filter by


Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions

Jacob McCann, Megan Ellis, Sean McGee, Kathryn Aston-Mourney

(2019), Vol. 11, pp. 112-118, Islets, Abingdon, Eng., C1


Metformin, beta-cell development, and novel processes following beta-cell ablation in zebrafish

G Wyett, Y Gibert, M Ellis, H Castillo, J Kaslin, K Aston-Mourney

(2018), Vol. 59, pp. 419-425, Endocrine, Totowa, N.J., C1-1


APP deficiency results in resistance to obesity but impairs glucose tolerance upon high fat feeding

J Czeczor, A Genders, K Aston-Mourney, T Connor, L Hall, K Hasebe, M Ellis, K De Jong, D Henstridge, P Meikle, M Febbraio, K Walder, S McGee

(2018), Vol. 237, pp. 311-322, Journal of endocrinology, Bradley Stok, Eng., C1


Gene expression signature: a powerful approach for drug discovery in diabetes

S Sithara, T Crowley, K Walder, K Aston-Mourney

(2017), Vol. 232, pp. R131-R139, Journal of endocrinology, Bristol, Eng., C1


Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice

V Gaur, T Connor, K Venardos, D Henstridge, S Martin, C Swinton, S Morrison, K Aston-Mourney, S Gehrig, R van Ewijk, G Lynch, M Febbraio, G Steinberg, M Hargreaves, K Walder, S McGee

(2017), Vol. 19, pp. 936-943, Diabetes, obesity and metabolism, Chichester, Eng., C1


Pathways of acetyl-CoA metabolism involved in the reversal of palmitate-induced glucose production by metformin and salicylate

B Hayward, J Molero, K Windmill, A Sanigorski, J Weir, N McRae, K Aston-Mourney, B Osborne, B Liao, K Walder, P Meikle, N Konstantopoulos, C Schmitz-Peiffer

(2016), Vol. 124, pp. 602-612, Experimental and clinical endocrinology and diabetes, Munich, Germany, C1


One year of sitagliptin treatment protects against islet amyloid-associated ?-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice

K Aston-Mourney, S Subramanian, S Zraika, T Samarasekera, D Meier, L Goldstein, R Hull

(2013), Vol. 305, American Journal of Physiology - Endocrinology and Metabolism, C1


Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis

M Smits, P Woudstra, K Utzschneider, J Tong, F Gerchman, M Faulenbach, D Carr, K Aston-Mourney, A Chait, R Knopp, J Meigs, E Boyko, S Kahn

(2013), Vol. 23, pp. 415-421, Annals of Epidemiology, C1-1


Rosiglitazone treatment does not decrease amyloid deposition in transplanted islets from transgenic mice expressing human islet amyloid polypeptide

J Udayasankar, S Zraika, K Aston-Mourney, S Subramanian, B Brooks-Worrell, G Taborsky, R Hull

(2013), Vol. 45, pp. 574-579, Transplantation Proceedings, C1-1


Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide

K Aston-Mourney, S Zraika, J Udayasankar, S Subramanian, P Green, S Kahn, R Hull

(2013), Vol. 288, pp. 3553-3559, Journal of Biological Chemistry, C1


CJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets

S Subramanian, R Hull, S Zraika, K Aston-Mourney, J Udayasankar, S Kahn

(2012), Vol. 55, pp. 166-174, Diabetologia, C1-1


?-Cell loss and ?-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition

C Jurgens, M Toukatly, C Fligner, J Udayasankar, S Subramanian, S Zraika, K Aston-Mourney, D Carr, P Westermark, G Westermark, S Kahn, R Hull

(2011), Vol. 178, pp. 2632-2640, American Journal of Pathology, C1-1


Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets

K Aston-Mourney, R Hull, S Zraika, J Udayasankar, S Subramanian, S Kahn

(2011), Vol. 54, pp. 1756-1765, Diabetologia, C1-1


Neprilysin impedes islet amyloid formation by inhibition ofs fibril formation rather than peptide degradation

S Zraika, K Aston-Mourney, P Marek, R Hull, P Green, J Udayasankar, S Subramanian, D Raleigh, S Kahn

(2010), Vol. 285, pp. 18177-18183, Journal of Biological Chemistry, C1-1


Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets

J Udayasankar, K Kodama, R Hull, S Zraika, K Aston-Mourney, S Subramanian, J Tong, M Faulenbach, J Vidal, S Kahn

(2009), Vol. 52, pp. 145-153, Diabetologia, C1-1


Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis

S Zraika, R Hull, J Udayasankar, K Aston-Mourney, S Subramanian, R Kisilevsky, W Szarek, S Kahn

(2009), Vol. 52, pp. 626-635, Diabetologia, C1-1


Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress

R Hull, S Zraika, J Udayasankar, K Aston-Mourney, S Subramanian, S Kahn

(2009), Vol. 52, pp. 1102-1111, Diabetologia, C1-1


Fructose-1,6-bisphosphatase overexpression in pancreatic ?-cells results in reduced insulin secretion: A new mechanism for fat-induced impairment of ?-cell function

M Kebede, J Favaloro, J Gunton, D Laybutt, M Shaw, N Wong, B Fam, K Aston-Mourney, C Rantzau, A Zulli, J Proietto, S Andrikopoulos

(2008), Vol. 57, pp. 1887-1895, Diabetes, C1-1


Too much of a good thing: Why it is bad to stimulate the beta cell to secrete insulin

K Aston-Mourney, J Proietto, G Morahan, S Andrikopoulos

(2008), Vol. 51, pp. 540-545, Diabetologia, C1-1


Increased nicotinamide nucleotide transhydrogenase levels predispose to insulin hypersecretion in a mouse strain susceptible to diabetes

K Aston-Mourney, N Wong, M Kebede, S Zraika, L Balmer, J McMahon, B Fam, J Favaloro, J Proietto, G Morahan, S Andrikopoulos

(2007), Vol. 50, pp. 2476-2485, Diabetologia, C1-1


The influence of genetic background on the induction of oxidative stress and impaired insulin secretion in mouse islets

S Zraika, K Aston-Mourney, D Laybutt, M Kebede, M Dunlop, J Proietto, S Andrikopoulos

(2006), Vol. 49, pp. 1254-1263, Diabetologia, C1-1


Investigational agents that protect pancreatic islet ?-cells from failure

K Aston-Mourney, J Proietto, S Andrikopoulos

(2005), Vol. 14, pp. 1241-1250, Expert Opinion on Investigational Drugs, C1-1


Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet

S Andrikopoulos, C Massa, K Aston-Mourney, A Funkat, B Fam, R Hull, S Kahn, J Proietto

(2005), Vol. 187, pp. 45-53, Journal of Endocrinology, C1-1


High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction

S Kooptiwut, M Kebede, S Zraika, S Visinoni, K Aston-Mourney, J Favaloro, C Tikellis, M Thomas, J Forbes, M Cooper, M Dunlop, J Proietto, S Andrikopoulos

(2005), Vol. 35, pp. 39-48, Journal of Molecular Endocrinology, C1-1


Funded Projects at Deakin

Other Public Sector Funding

MiSeq Next Generation Sequencer

Dr Kathryn Aston-Mourney

  • 2013: $15,000

Industry and Other Funding

JDRF Travel Grant

Dr Kathryn Aston-Mourney

  • 2012: $3,170

HDAC Inhibition as a Potential Therapy for Preventing the Progression of Type 2 Diabetes

Dr Kathryn Aston-Mourney, A/Prof Sean Mcgee

  • 2015: $55,000

Generation and application of a novel screening tool for the Discovery of b-cell Protective Diabetes Drugs

Dr Kathryn Aston-Mourney

  • 2015: $20,650

Discovery of novel therapies for type 2 diabetes

Dr Kathryn Aston-Mourney

  • 2015: $32,000

Other Funding Sources

CASS Travel grant - American Diabetes Foundation

Dr Kathryn Aston-Mourney

  • 2012: $3,000


Principal Supervisor

Smithamol Sithara

Thesis entitled: A beta-cell specific global approach for drug identification in Type 2 Diabetes

Doctor of Philosophy (Medicine), School of Medicine